A Phase 1/2 interventional study of BMS-986369 in Relapsed or Refractory T-cell Lymphomas, sponsored by Bristol-Myers Squibb. Active, not recruiting at 40 sites in Japan. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2026-10-07.
Sponsored by Bristol-Myers Squibb · Phase 1/2, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
The purpose of this study is to test the safety, tolerability, efficacy, and drug levels of BMS-986369 (Golcadomide) in participants with relapsed or refractory T-cell lymphomas in Japan (GOLSEEK-3).
310 studies on the registry are indexed under Lymphoma, T-Cell; 77 are open to participants now.
This study's planned enrollment of 83 is above the median of 37 across 270 interventional studies indexed under Lymphoma, T-Cell.
Browse Lymphoma, T-Cell studies →Bristol-Myers Squibb is the lead sponsor of 1,561 studies on the registry; 118 are open to participants now.
Of its 436 completed or terminated interventional studies of FDA-regulated products, 228 (52%) have results posted.
Compared within Lymphoma, T-Cell, this study's primary condition as ClinicalTrials.gg classifies it; the registry's first condition term is Recurrence. The counts are of registry records indexed under each term, refreshed daily. How we classify →
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
- Have one of the following subtypes of T-cell Lymphoma (TCL) with disease, as assessed by the investigator:.
i) Adult T-cell leukemia-lymphoma (ATL).
ii) Peripheral T-cell lymphoma not otherwise specified (PTCL-NOS).
iii) Angioimmunoblastic T-cell lymphoma (AITL) and other nodal lymphomas of T follicular helper phenotype (TFH) cell origin.
iv) Anaplastic large cell lymphoma (ALCL), anaplastic lymphoma kinase-positive (ALK+).
v) ALCL, anaplastic lymphoma kinase-negative (ALK-).
vi) Breast implant-associated ALCL.
vii) Extranodal NK/T-cell lymphoma, nasal type (ENKL).
viii) Mycosis fungoides (MF) with advanced stage (stage IIB-IVB).
Exclusion Criteria
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Relapsed: the illness came back after treatment had worked. Refractory: it did not respond to treatment, or stopped responding while still on it.
A line of therapy is one course of treatment, which may combine several drugs. First-line is the first course given; second-line follows when that stops working or is not tolerated.
“Two prior lines” means two courses that count separately under the study’s rules — not simply two drugs. Ask the study team if you are unsure how yours are counted.
A scale of how much an illness limits everyday activity. For people being assessed to join a study, scores run from 0 (fully active) to 4; lower is more active.
Studies most often ask for 0–1 or 0–2. Your doctor gives the score; the WHO scale uses the same steps. The full scale also has 5, which records death.
The study doctor’s estimate of how long someone is likely to live. Criteria use it so that people can stay in the study long enough for it to answer its question.
Relapsed and refractory
Relapsed: the illness came back after treatment had worked. Refractory: it did not respond to treatment, or stopped responding while still on it.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Line of therapy
A line of therapy is one course of treatment, which may combine several drugs. First-line is the first course given; second-line follows when that stops working or is not tolerated.
“Two prior lines” means two courses that count separately under the study’s rules — not simply two drugs. Ask the study team if you are unsure how yours are counted.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
ECOG performance status
A scale of how much an illness limits everyday activity. For people being assessed to join a study, scores run from 0 (fully active) to 4; lower is more active.
Studies most often ask for 0–1 or 0–2. Your doctor gives the score; the WHO scale uses the same steps. The full scale also has 5, which records death.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Life expectancy
The study doctor’s estimate of how long someone is likely to live. Criteria use it so that people can stay in the study long enough for it to answer its question.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Drug: BMS-986369
Specified dose on specified days
Also known as: Golcadomide, CC-99282
Number of participants with Adverse Events (AEs)
Phase 1 participants
Time frame: Up to 5 weeks after last dose of treatment
Number of participants with treatment-emergent adverse events (TEAEs)
Phase 1 participants
Time frame: Up to 5 weeks after last dose of treatment
Number of participants with Dose-Limiting Toxicity (DLT)
Phase 1 participants
Time frame: Up to 28 days after first dose
Number of participants with laboratory abnormalities
Phase 1 participants
Time frame: Up to 5 weeks after last dose of treatment
Number of participants with vital sign abnormalities
Phase 1 participants
Time frame: Up to 5 weeks after last dose of treatment
Number of participants with Electrocardiogram (ECG) abnormalities
Phase 1 participants
Time frame: Up to 5 weeks after last dose of treatment
Eastern Cooperative Oncology Group Performance Status (ECOG PS)
Phase 1 participants
Time frame: Up to 5 weeks after last dose of treatment
Number of participants with Left Ventricular Ejection Fraction (LVEF) assessment abnormalities
Phase 1 participants
Time frame: Up to 5 weeks after last dose of treatment
Number of participants with Physical Examination (PE) abnormalities
Phase 1 participants
Time frame: Up to 5 weeks after last dose of treatment
Number of participants who achieve Objective Response (OR) as assessed by central review per international consensus response criteria for ATL
Phase 2: Adult T-cell Leukemia-Lymphoma (ATL) cohort OR is defined as the achievement of Partial Response (PR), complete response unconfirmed (CRu), or Complete Response (CR)
Time frame: Up to 2 years after last does of treatment
Number of participants who achieve OR as assessed by central review per protocol-defined response criteria according to Lugano classification (Computed Tomography(CT)-based)
Phase 2: Peripheral T-cell Lymphoma (PTCL) cohort OR is defined as the achievement of PR or CR
Time frame: Up to 2 years after last dose of treatment
Maximum observed plasma concentration (Cmax)
Time frame: Up to Day 8 of Cycle 2 (each cycle is 28 days)
Area under the plasma concentration time-curve (AUC)
Time frame: Up to Day 8 of Cycle 2 (each cycle is 28 days)
Time to peak (maximum) plasma concentration (Tmax)
Time frame: Up to Day 8 of Cycle 2 (each cycle is 28 days)
Number of participants with AEs
Phase 2 participants
Time frame: Up to 5 weeks after last dose of treatment
Number of participants with TEAEs
Phase 2 participants
Time frame: Up to 5 weeks after last dose of treatment
Number of participants with laboratory abnormalities
Phase 2 participants
Time frame: Up to 5 weeks after last dose of treatment
Number of participants with vital sign abnormalities
Phase 2 participants
Time frame: Up to 5 weeks after last dose of treatment
Number of participants with ECG abnormalities
Phase 2 participants
Time frame: Up to 5 weeks after last dose of treatment
ECOG PS
Phase 2 participants
Time frame: Up to 5 weeks after last dose of treatment
Number of participants with LVEF assessment abnormalities
Phase 2 participants
Time frame: Up to 5 weeks after last dose of treatment
Number of participants with PE abnormalities
Phase 2 participants
Time frame: Up to 5 weeks after last dose of treatment
Number of participants who achieve OR as assessed by central review per international consensus response criteria for ATL
ATL participants OR is defined as the achievement of PR, CRu, or CR
Time frame: Up to 4 years after last dose of treatment
Number of participants who achieve OR as assessed by investigator per international consensus response criteria for ATL
ATL participants OR is defined as the achievement of PR, CRu, or CR
Time frame: Up to 4 years after last dose of treatment
Number of participants who achieve OR as assessed by central review per protocol defined response criteria according to Lugano classification (CT-based).
PTCL participants OR is defined as the achievement of PR or CR
Time frame: Up to 4 years after last dose of treatment
Number of participants who achieve OR as assessed by investigator per protocol defined response criteria according to Lugano classification (CT-based).
PTCL participants OR is defined as the achievement of PR or CR
Time frame: Up to 4 years after last dose of treatment
Number of participants who achieve disease control as assessed by central review per international consensus response criteria for ATL
ATL participants Disease control is considered to be stable disease (SD), PR, CRu, or CR
Time frame: Up to 4 years after last dose of treatment
Number of participants who achieve disease control as assessed by investigator per international consensus response criteria for ATL
ATL participants Disease control is considered to be SD, PR, CRu, or CR
Time frame: Up to 4 years after last dose of treatment
Number of participants who achieve CR as assessed by central review per international consensus response criteria for ATL
ATL participants
Time frame: Up to 4 years after last dose of treatment
Number of participants who achieve CR as assessed by investigator per international consensus response criteria for ATL
ATL participants
Time frame: Up to 4 years after last dose of treatment
Time to response (TTR) as assessed by central review per international consensus response criteria for ATL
ATL participants
Time frame: Up to 4 years after last dose of treatment
TTR as assessed by investigator per international consensus response criteria for ATL
ATL participants
Time frame: Up to 4 years after last dose of treatment
Duration of response (DOR) as assessed by central review per international consensus response criteria for ATL
ATL Participants
Time frame: Up to 4 years after last dose of treatment
DOR as assessed by investigator per international consensus response criteria for ATL
ATL Participants
Time frame: Up to 4 years after last dose of treatment
Progression Free Survival (PFS) as assessed by central review per international consensus response criteria for ATL
ATL participants
Time frame: Up to 4 years after last dose of treatment
PFS as assessed by investigator per international consensus response criteria for ATL
ATL participants
Time frame: Up to 4 years after last dose of treatment
Number of participants who achieve disease control as assessed by central review per protocol defined response criteria according to Lugano classification (CT-based)
PTCL participants Disease control is considered to be SD, PR or CR
Time frame: Up to 4 years after last dose of treatment
Number of participants who achieve disease control as assessed by investigator per protocol defined response criteria according to Lugano classification (CT-based)
PTCL participants Disease control is considered to be SD, PR or CR
Time frame: Up to 4 years after last dose of treatment
Number of participants who achieve CR as assessed by central review per protocol defined response criteria according to Lugano classification (CT-based)
PTCL participants
Time frame: Up to 4 years after last dose of treatment
Number of participants who achieve CR as assessed by investigator per protocol defined response criteria according to Lugano classification (CT-based)
PTCL participants
Time frame: Up to 4 years after last dose of treatment
TTR as assessed by central review per protocol defined response criteria according to Lugano classification (CT-based)
PTCL participants
Time frame: Up to 4 years after last dose of treatment
TTR as assessed by investigator per protocol defined response criteria according to Lugano classification (CT-based)
PTCL participants
Time frame: Up to 4 years after last dose of treatment
DOR as assessed by central review per protocol defined response criteria according to Lugano classification (CT-based)
PTCL participants
Time frame: Up to 4 years after last dose of treatment
DOR as assessed by investigator per protocol defined response criteria according to Lugano classification (CT-based)
PTCL participants
Time frame: Up to 4 years after last dose of treatment
PFS as assessed by central review per protocol defined response criteria according to Lugano classification (CT-based)
PTCL participants
Time frame: Up to 4 years after last dose of treatment
PFS as assessed by investigator per protocol defined response criteria according to Lugano classification (CT-based)
PTCL participants
Time frame: Up to 4 years after last dose of treatment
Time to next treatment (TTNT)
Time frame: From the date of last dose until the date of death, lost to follow-up, withdrawal of consent from the entire study, time to next treatment or the end of the trial, whichever occurs first, assessed up to 2 years after end of treatment.
Overall survival (OS)
Time frame: From the date of last dose until the date of death, lost to follow-up, withdrawal of consent from the entire study, or the end of the trial, whichever occurs first, assessed up to 2 years after end of treatment.
Plan to share: Yes — BMS will provide access to individual anonymized participant data upon request from qualified researchers, and subject to certain criteria. Additional information regarding Bristol Myer Squibb's data sharing policy and process can be found at https://www.bms.com/researchers-and-partners/clinical-trials-and-research.html
Supporting information: Study protocol, Statistical analysis plan, Clinical study report
Time frame: See Plan Description
Access criteria: See Plan Description
Data sharing details ↗ · www.bms.com
Ran from Nov 2023 to primary completion in Aug 2026, 32 months.
Of 29 phase 1/2 interventional studies under Lymphoma, T-Cell, half reached primary completion within 62 months of starting (the median), counting those still running; a quarter within 49 and three quarters within 92. This study's 32 months is below that.
Primary completion moved once since we started tracking on Sep 25, 2026: Jan 2027 → Aug 2026, on Oct 7, 2026.
Earlier changes are on the record history on ClinicalTrials.gov ↗
How these figures are worked out, and which studies are left out of them.
From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗
This study is active, not recruiting, as verified in Oct 2026. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drug tested here: Golcadomide